c-MET Detection Service

The transmembrane tyrosine-protein kinase receptor Met (c-MET) is a protein related to cell proliferation, invasion and angiogenesis, it is expressed in a variety of cancers, and has the potential to be a prognostic biomarker for a variety of cancers. Creative BioMart Biomarker as a provider of technical services in the field of biomarkers, provides customers with high-quality cancer biomarker detection services. Fast, accurate and reliable detection, and reasonable prices can effectively help customers shorten the research cycle and reduce research costs.

c-MET and Cancers

c-MET is a protein with tyrosine kinase activity encoded by MET gene, also known as hepatocyte growth factor receptor (HGFR). HGF is a ligand of c-MET, and participates in many physiological activities such as cell proliferation, invasion and angiogenesis together with c-MET. c-MET binds to HGF and dimerizes and autophosphorylates, creating active docking sites for proteins that mediate downstream signaling pathways, which ultimately leads to the activation of multiple signaling pathways, including phosphatidylinositol 3-kinase (PI3K)-AKT, mitogen -activated protein kinase (MAPK), signal transducer and activator of transcription (STAT) signaling pathways. The activation of these signal pathways can promote various physiological activities including cell growth, invasion, branching morphogenesis, protection from apoptosis and angiogenesis. In a variety of cancers, including lung cancer, breast cancer, liver cancer, gastric carcinomas, ovarian cancer, colon cancer, thyroid cancer, etc., c-MET is overexpressed. Moreover, the inappropriate activation of c-MET will promote the ability of cancer cell proliferation, invasion or metastasis. In addition, c-MET has an indicator effect on the prognosis of cancer, and has the potential to be used as a prognostic biomarker for various cancers. For example, in lung adenocarcinoma, high expression of c-MET may mean increased growth rate of tumor cells and the occurrence of metastasis, and at the same time, its overexpression may indicate resistance to radiotherapy and poor prognosis. In addition, in breast cancer, the high expression of c-MET is related to poor prognosis, disease grade and metastasis rate.

Figure 1. HGF binding c-MET activates signaling cascades (Levi, et al. 2017)

Application of c-MET Detection

Plasma and serum c-MET levels can be used as biomarkers in researches related to lung cancer, breast cancer, liver cancer, gastric carcinomas, ovarian cancer, colon cancer, thyroid cancer, etc.

Our Advantages

• Guarantee high accuracy and sensitivity for c-MET detection
• Ensure high repeatability of c-MET detection
• Short turn-around time of detection service
• Competitive price in the market of c-MET detection services
• Multiple technology platforms for c-MET test services (ELISA, ECL)
• Accept a wide range of sample types (plasma, serum, cell culture supernatants, etc.)

Workflow of Biomarker Detection at Creative BioMart Biomarker

Creative BioMart Biomarker strictly controls each specific experimental step in the detection procedure to ensure accurately quantify the level of c-MET in each sample.